DEXWireNews

Chembio Diagnostics 20% upside

ロング
NASDAQ:CEMI   None
Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The firm expanding its product portfolio based upon the proprietary Dual Path Platform, which uses a small drop of blood from the fingertip to provide cost-effective diagnostic results in approximately 15 minutes. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Hauppauge, NY.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media
免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。